Analyzing prognosis and risk factors for acute kidney injury

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to analyze the diagnosis and prognosis of acute kidney injury (AKI) by assessing its severity and defining long-term clinical and socioeconomic outcomes. It involves adults aged 20 years or older who visited participating medical centers and underwent at least two blood tests for serum creatinine within a week. The study population includes an AKI group, defined by specific diagnostic criteria, and a matched control group based on age, sex, and baseline kidney function. Various clinical, laboratory, and hospitalization records will be collected and analyzed to understand the implications of AKI.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults over 20 years old who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021
* The AKI group is defined as individuals meeting the AKI diagnostic criteria of the KDIGO Guideline (an increase in serum creatinine of ≥0.3 mg/dL or ≥1.5 times the baseline level) is enrolled.
* The Control Group is defined as individuals from the study population who do not meet the AKI criteria and are matched 1:1 based on age, sex, year of visit, and baseline renal function.

Exclusion Criteria:

* Individuals under 20 years old
* Individuals who did not undergo serum creatinine tests meeting the criteria
* Individuals with pre-existing end-stage kidney disease (ESKD) who have undergone dialysis or kidney transplantation

Where it's running

• Seoul National University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Dong Ki Kim, M.D. Ph.D. — Department of Internal Medicine, Seoul National University Hospital
• Study coordinator: Sehoon Park, M.D. Ph.D.
• Email: mailofsehoon@gmail.com
• Phone: +82-02-2072-4070

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

• Restarting RAS inhibitors after AKI: a quick test in hospitalized adults

  This pilot study tests whether restarting renin-angiotensin system inhibitors early after acute kidney injury is feasible and safe in hospitalized adults already using these medicines.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT07734636

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.